Literature DB >> 30706088

Physical, Mental, and Social Problems of Adolescent and Adult Patients with Achondroplasia.

Masaki Matsushita1, Hiroshi Kitoh2, Kenichi Mishima2, Satoshi Yamashita3, Nobuhiko Haga4, Sayaka Fujiwara4, Keiichi Ozono5, Takuo Kubota5, Taichi Kitaoka5, Naoki Ishiguro2.   

Abstract

Patients with achondroplasia (ACH) require various medical interventions throughout the lifetime. Survey of health-related quality of life (HRQoL) in adult ACH patients is essential for the evaluation of treatment outcomes performed during childhood such as growth hormone administration and limb lengthening surgeries, but no study focused on the treatment strategy by analyzing HRQoL of ACH patients. The purpose of this study was to assess whether final height impacted on HRQoL and to evaluate what kinds of medical interventions were positively or negatively associated with HRQoL. We included 184 ACH patients (10-67 years old) who were registered in the patients' associations or who had a medical history of the investigators' institutions, and analyzed HRQoL by using Short Form-36 and patient demographics. Physical component summary (PCS) was significantly lower than the standard values in each age, especially in elderly populations, while mental component summary (MCS) was similar to the standard values. Role/social component summary was deteriorated only in elderly populations. The PCS was improved in the patients who had a height of 140 cm or taller (p < 0.001). The PCS and MCS were strongly associated with the past medical history of spine surgeries (p < 0.001 and p = 0.028, respectively). A treatment strategy would be planned to gain a final height of 140 cm or taller during childhood in combination with growth hormone administration and limb lengthening surgeries. Appropriate medical management for neurological complications of adult ACH patients is required to maintain physical and mental function.

Entities:  

Keywords:  Achondroplasia; Height; Limb lengthening; Quality of life; SF-36; Spine

Mesh:

Year:  2019        PMID: 30706088     DOI: 10.1007/s00223-019-00518-z

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  14 in total

Review 1.  Disease-specific complications and multidisciplinary interventions in achondroplasia.

Authors:  Hiroshi Kitoh; Masaki Matsushita; Kenichi Mishima; Yasunari Kamiya; Kenta Sawamura
Journal:  J Bone Miner Metab       Date:  2022-01-14       Impact factor: 2.626

2.  Treatment Goals for Achondroplasia: A Qualitative Study with Parents and Adults.

Authors:  Sarah A McGraw; Jeff C Henne; James Nutter; Adelpha Abrahamson Larkin; Er Chen
Journal:  Adv Ther       Date:  2022-06-08       Impact factor: 4.070

Review 3.  International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia.

Authors:  Ravi Savarirayan; Penny Ireland; Melita Irving; Dominic Thompson; Inês Alves; Wagner A R Baratela; James Betts; Michael B Bober; Silvio Boero; Jenna Briddell; Jeffrey Campbell; Philippe M Campeau; Patricia Carl-Innig; Moira S Cheung; Martyn Cobourne; Valérie Cormier-Daire; Muriel Deladure-Molla; Mariana Del Pino; Heather Elphick; Virginia Fano; Brigitte Fauroux; Jonathan Gibbins; Mari L Groves; Lars Hagenäs; Therese Hannon; Julie Hoover-Fong; Morrys Kaisermann; Antonio Leiva-Gea; Juan Llerena; William Mackenzie; Kenneth Martin; Fabio Mazzoleni; Sharon McDonnell; Maria Costanza Meazzini; Josef Milerad; Klaus Mohnike; Geert R Mortier; Amaka Offiah; Keiichi Ozono; John A Phillips; Steven Powell; Yosha Prasad; Cathleen Raggio; Pablo Rosselli; Judith Rossiter; Angelo Selicorni; Marco Sessa; Mary Theroux; Matthew Thomas; Laura Trespedi; David Tunkel; Colin Wallis; Michael Wright; Natsuo Yasui; Svein Otto Fredwall
Journal:  Nat Rev Endocrinol       Date:  2021-11-26       Impact factor: 47.564

4.  High prevalence of symptomatic spinal stenosis in Norwegian adults with achondroplasia: a population-based study.

Authors:  Svein O Fredwall; Unni Steen; Olga de Vries; Cecilie F Rustad; Heidi Beate Eggesbø; Harald Weedon-Fekjær; Ingeborg B Lidal; Ravi Savarirayan; Grethe Månum
Journal:  Orphanet J Rare Dis       Date:  2020-05-25       Impact factor: 4.123

5.  Inconvenience and adaptation in Japanese adult achondroplasia and hypochondroplasia: A cross-sectional study.

Authors:  Akiko Ajimi; Masaki Matsushita; Kenichi Mishima; Nobuhiko Haga; Sayaka Fujiwara; Keiichi Ozono; Takuo Kubota; Taichi Kitaoka; Shiro Imagama; Hiroshi Kitoh
Journal:  Clin Pediatr Endocrinol       Date:  2021-11-01

6.  Health-related Quality of Life in Adult Patients with Multiple Epiphyseal Dysplasia and Spondyloepiphyseal Dysplasia.

Authors:  Masaki Matsushita; Kenichi Mishima; Yasunari Kamiya; Nobuhiko Haga; Sayaka Fujiwara; Keiichi Ozono; Takuo Kubota; Taichi Kitaoka; Shiro Imagama; Hiroshi Kitoh
Journal:  Prog Rehabil Med       Date:  2021-12-07

7.  Quality of Life Evaluation Following Limb Lengthening Surgery in Patients with Achondroplasia.

Authors:  Sefa Giray Batıbay; Halil İbrahim Balcı; Serkan Bayram; Mehmet Chodza; Şeyda Göksoy; Önder Murat Hürmeydan; Aslı Derya Kardelen; Cengiz Şen; Mehmet Kocaoğlu
Journal:  Indian J Orthop       Date:  2020-05-04       Impact factor: 1.251

8.  Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia.

Authors:  Hiroshi Kitoh; Masaki Matsushita; Kenichi Mishima; Tadashi Nagata; Yasunari Kamiya; Kohei Ueda; Yachiyo Kuwatsuka; Hiroshi Morikawa; Yasuhiro Nakai; Naoki Ishiguro
Journal:  PLoS One       Date:  2020-04-13       Impact factor: 3.240

9.  Birth prevalence of achondroplasia: A systematic literature review and meta-analysis.

Authors:  Pamela K Foreman; Femke van Kessel; Rosa van Hoorn; Judith van den Bosch; Renée Shediac; Sarah Landis
Journal:  Am J Med Genet A       Date:  2020-08-17       Impact factor: 2.802

Review 10.  Extensive Limb Lengthening for Achondroplasia and Hypochondroplasia.

Authors:  Dror Paley
Journal:  Children (Basel)       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.